Shin Kabsoo, Kim Joori, Park Se Jun, Kim Hyunho, Lee Myung Ah, Kim Okran, Park Juyeon, Kang Nahyeon, Kim In-Ho
Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Cancers (Basel). 2023 Aug 3;15(15):3955. doi: 10.3390/cancers15153955.
The clinical significance of PD-1 expression in circulating CD8 T cells in patients with gastric cancer (GC) receiving chemotherapy remains unelucidated. Therefore, we aimed to examine its prognostic significance in blood samples of 68 patients with advanced GC who received platinum-based chemotherapy. The correlation between peripheral blood mononuclear cells, measured using fluorescence-activated cell sorting, was evaluated. Patients were divided into two groups according to the changes in PD-1CD8 T-cell frequencies between day 0 and 7. They were categorized as increased or decreased PD-1CD8 T-cell groups. The increased PD-1CD8 T-cell group showed longer progression-free survival (PFS) and overall survival (OS) than the decreased PD-1CD8 T-cell group (PFS: 8.7 months vs. 6.1 months, = 0.007; OS: 20.7 months vs. 10.8 months, = 0.003). The mean duration of response was significantly different between the groups (5.7 months vs. 2.5 months, = 0.041). Multivariate analysis revealed that an increase in PD-1CD8 T-cell frequency was an independent prognostic factor. We concluded that the early increase in PD-1CD8 T-cell frequency is a potential predictor of favorable prognoses and durable responses in patients with advanced GC receiving chemotherapy.
接受化疗的胃癌（GC）患者循环CD8 T细胞中PD-1表达的临床意义仍不明确。因此，我们旨在研究其在68例接受铂类化疗的晚期GC患者血液样本中的预后意义。评估了使用荧光激活细胞分选法测量的外周血单个核细胞之间的相关性。根据第0天和第7天之间PD-1⁺CD8 T细胞频率的变化将患者分为两组。它们被分类为PD-1⁺CD8 T细胞增加组或减少组。PD-1⁺CD8 T细胞增加组的无进展生存期（PFS）和总生存期（OS）比PD-1⁺CD8 T细胞减少组更长（PFS：8.7个月对6.1个月，P = 0.007；OS：20.7个月对10.8个月，P = 0.003）。两组之间的平均缓解持续时间有显著差异（5.7个月对2.5个月，P = 0.041）。多变量分析显示，PD-1⁺CD8 T细胞频率增加是一个独立的预后因素。我们得出结论，PD-1⁺CD8 T细胞频率的早期增加是接受化疗的晚期GC患者预后良好和持久缓解的潜在预测指标。
